<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Aurinia Pharmaceuticals ( (AUPH) ) just unveiled an update. On May 8, 2026, Aurinia Pharma U.S., Inc. completed a tender offer to acquire approximately 80.24% of Kezar Life Sciences’ outstanding common stock for $6.955 in cash per share plus one contingent value right, following a merger agreement signed on March 30, 2026. The remaining shares were converted in a follow-on merger completed on May 11, 2026, making Kezar a wholly owned subsidiary, with in-the-money stock options cashed out for cash and CVRs, out-of-the-money options cancelled without payment, and the company’s 2018 employee stock purchase plan terminated immediately prior to the merger’s effective time. The most recent analyst rating on (AUPH) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page. Spark’s Take on AUPH Stock According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform. The score is primarily driven by strong recent financial performance (profitability and free cash flow) and a supportive earnings outlook with continued LUPKYNIS growth and buybacks. This is tempered by mixed/neutral technical momentum, moderate valuation support, and sustainability risks tied to earnings volatility and the one-time tax benefit, plus competitive and regulatory uncertainties. To see Spark’s full report on AUPH stock, click here. More about Aurinia Pharmaceuticals Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies, particularly in immunology and related disease areas, through both internal programs and strategic acquisitions. Its U.S. subsidiary, Aurinia Pharma U.S., Inc., serves as the primary vehicle for corporate transactions and expansion in the American market. Average Trading Volume: 1,118,672 Technical Sentiment Signal: Buy Current Market Cap: $1.96B </div>

AUPH

SBIO

Aurinia Pharmaceuticals has completed the acquisition of approximately 80.24% of Kezar Life Sciences' outstanding common stock for $6.955 per share, following a merger agreement signed on March 30, 2026. The remaining shares were converted in a follow-on merger, making Kezar a wholly owned subsidiary. The latest analyst rating for Aurinia (AUPH) is a Hold with a $15.00 price target, while Spark's AI Analyst rates it as Outperform due to strong financial performance and growth outlook, despite some risks.

Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences